Malignant solid tumors
Conditions
Interventions
Observation group:None
Sponsors
The First Hospital of Nanping City, Fujian Province
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.The study included participants whose age was 18 years or older at the time of enrollment, with no restrictions on gender. 2.Patients who have been clinically diagnosed with malignant solid tumors and have failed standard treatment, including but not limited to lung cancer, liver cancer, gastric cancer, colorectal cancer, esophageal cancer, breast cancer, cervical cancer, ovarian cancer, endometrial cancer, nasopharyngeal cancer, biliary tract cancer, etc. 3.The plan is to administer Iparomlimab and Tuvonralimab injection for treatment after the patients are enrolled. 4.The patient fully understood this study and voluntarily participated, providing a written informed consent form. Data collection can only be carried out after obtaining the written informed consent form.
Exclusion criteria
Exclusion criteria: 1.Patients with brain metastases who have cognitive impairments or those with other neurological or psychiatric disorders; 2.Those who are known to be allergic to the studied drug or its similar preparations, or to other biological products, or who are contraindicated or advised to use with caution. 3.Other researchers believe that certain circumstances are not suitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Health-related quality of life; | — |
Secondary
| Measure | Time frame |
|---|---|
| One-year/Two-year Overall Survival Rate;Duration of relief;Overall survival time;Disease control rate;Progression-free survival time;One-year / Two-year PFS rate;Treatment-related adverse event; | — |
Countries
China
Contacts
Public ContactYing Zhong
The First Hospital of Nanping City, Fujian Province
Outcome results
None listed